Latest changes
This category tracks 375 sources on GovPing, covering Guidance, Enforcement, Rule, FAQ, Notice, and Consultation instruments across 3,297 total sources. There were 1,626 changes in the last 7 days.
The California Board of Pharmacy revoked 12 licenses effective April 1, 2026. Dr. Gerald Buchoff was ordered to pay $7,500 for negligence in treating a Yorkshire Terrier. Health Canada recalled Max Slim capsules for undeclared caffeine, and ANSM recalled 847 Namic syringes over burn risks.
Tissue Isolation Balloon Device for Radiotherapy
USPTO published patent application US20260097233A1, filed December 12, 2025, assigned to Beijing Qifan Bochuang Medical Technology Co., Ltd. The application covers a tissue isolation balloon device designed for repeated inflation and deflation in vivo during radiotherapy courses, with an isolation balloon positioned between healthy and target tissues to protect healthy tissue from radiation exposure.
E-Vaping Device Formulation Level Indicator Patent Application
The USPTO published patent application US20260097173A1 for Altria Client Services LLC covering an electronic vaping device with a pre-vapor formulation level indicator. The device includes a vaporizer assembly with heating element, pre-vapor formulation reservoir, and discrete indicator segments controlled by a processor that determines duty cycle differences to adjust the indicator. The three inventors are Terrance Theodore Bache, Christopher S. Tucker, and Raymond W. Lau.
Multi Chamber Flexible Bag and Methods of Using Same
USPTO published patent application US20260096952A1 by inventor Antonio Francesco Di Naro for a multi-chamber flexible pharmaceutical bag designed to hold lyophilized products with a reconstituting solution. The bag features a frangible seal between chambers that breaks upon application of predetermined force to fluidly connect the chambers.
Antibody Compositions with Antioxidants for Subcutaneous Delivery
The USPTO published patent application US20260097118A1 assigned to Bristol-Myers Squibb Company, covering pharmaceutical compositions comprising an antibody and at least two antioxidants formulated for subcutaneous delivery. The application includes claims for methods using an endoglycosidase hydrolase enzyme in the composition. Filing date was September 29, 2025.
Aptar France Sas Spray Patent Analysis Method
USPTO published patent application US20260097411A1 assigned to Aptar France SAS, covering a method for analyzing spray generated by pharmaceutical fluid dispensing devices. The method uses strioscopy to display test fluid flow and determines spray compliance with specifications. Cycle time for analyzing one spray head is under 1.5 seconds.
Cancer Therapy Delivery System with Tumbling Container for Suspension Generation
USPTO published patent application US20260096951A1 for a cancer therapy delivery system featuring a tumbler vial for generating therapeutic microsphere suspensions. The system includes a rotation mechanism, fluid inlet and outlet lines configured to twist during rotation, and a cap occluding the vial end. The application was filed on October 9, 2025.
Novel Formulations and Vehicles for DAPTZ Compounds Including Methylene Blue
USPTO published patent application US20260097043A1 assigned to WisTa Laboratories Ltd., covering novel oral pharmaceutical formulations of diaminophenothiazine (DAPTZ) compounds such as methylene blue. The application discloses gastro-retentive platforms including film-coated solid tablets and buoyant self-orientating capsules with sustained-release coatings. The filing was submitted on September 20, 2023, under application number 19113777.
Cholesterol Efflux Modulation Compositions and Methods - US20260097053A1
USPTO published patent application US20260097053A1 for compositions and methods modulating cholesterol efflux via ABCA1 for treating atherosclerosis and related diseases. Invented by Kailash Gulshan, the application claims PIP2 compositions affecting ABCA1 levels and promoting reverse cholesterol transport (RCT) to reduce cholesterol and atherosclerosis. This is a patent application publication establishing a filing date, not a granted patent.
Ostomy Appliance Patent Application US20260096916A1
The USPTO published patent application US20260096916A1 for an ostomy appliance comprising a barrier with multiple layers (top layer with upper/lower piles, reinforcing layer, adherent layer with silicone gel) and an attached pouch. Inventors: Thomas R. Galbierz and Michael A. Galbierz. Application No. 19349631 filed October 3, 2025.
Urine Collection and Drainage Device and Methods of Use Thereof
The USPTO published patent application US20260096917A1 filed by LampLight Innovations, Inc. for an improved urine collection and drainage device. The application, filed October 7, 2025, was published April 9, 2026. The device comprises a vulva-facing portion with a bulbous protuberance, posterior ridge, and partial dome portion, along with a urine collection slot and a urine collection bag folded to create a one-way valve.
Implantable Device for Administering a Therapeutic Agent
USPTO published patent application US20260096984A1 filed by inventors Harsh Patel and Jeffrey Haley on October 3, 2025. The application covers an implantable device for delivering therapeutic agents, featuring a core polymer matrix with hydrophobic poly ortho ester (POE) polymer having a glass transition temperature between -20°C and 40°C. The device is designed for controlled therapeutic agent release in vivo.
Solanum Lycopersicum Plants Having Improved Tobamovirus Resistance
The USPTO published patent application US20260096533A1 granting protection for hybrid Solanum lycopersicum tomato plants containing the Rug-1 resistance gene that confers Tomato Brown Rugose Fruit Virus (ToBRFV) tolerance/resistance. The patent covers the plant, seeds, fruits, plant parts, and methods for identifying, selecting, and producing ToBRFV-resistant tomato plants using the specified genetic marker.
Understanding Responsibilities When Importing, Compounding and Supplying Unapproved Peptide Products
TGA has published a safety advisory warning of rising import, supply, compounding and advertising of unapproved peptide products in Australia. Products containing BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295 are specifically identified as unapproved goods not evaluated for safety, quality, or effectiveness. The TGA states it is actively monitoring this issue from both safety and law enforcement perspectives and reminds affected parties of their obligations under the Therapeutic Goods Act 1989.
Solid Dispersions Having Stabilized Emulsion Particles Patent Application
USPTO published patent application US20260096994A1 for solid dispersion compositions containing active pharmaceutical ingredients and dispersion carriers. The application covers methods of dissolving API with carriers, combining with anti-solvent containing surfactant to form emulsions, and removing solvent to achieve predetermined particle size ranges. The application notably includes Compound (1) (zongertinib).
Teardrop Effervescent Tablet, Rapid Dissolution, Oral Drug Delivery
USPTO published patent application US20260096993A1 for a teardrop-shaped effervescent tablet designed for rapid dissolution oral drug delivery. The application (No. 18909065) was filed on October 8, 2024 and published April 9, 2026. Inventors Philip Mackenzie and Dan Aziz disclose a tablet with asymmetric geometry and cupped surfaces engineered to accelerate dissolution rates and improve bioavailability of active ingredients.
Biodegradable Microcapsules and Method for Their Preparation
USPTO published patent application US20260096991A1 for biodegradable microcapsules and methods for their preparation. The application relates to microcapsule compositions for drug delivery, classified under A61K. Filing date was September 7, 2023, with nine listed inventors.
Polymeric Delivery System Patent for Biologics
USPTO published patent application US20260096990A1 for a polymeric delivery system designed to deliver biologic therapeutics to cells. The invention covers polyplexes composed of charged polyesters and biologics, as well as self-assembled particles with block copolymers. The application was filed on December 12, 2025, by inventors Jeremy J. Harris, Scott Radzinski, Brian Ginn, Peter D. Gabriele, and Benjamin Roadarmel.
Infusion Pump Mechanism with Occlusion Force Reduction
The USPTO published patent application US20260097166A1 for an infusion pump mechanism featuring multi-directional tolerance control to reduce occlusion force. The invention includes pump fingers with head portions having tips configured to contact and occlude tubes, and an opposing plate with force concentrators aligned with respective pump fingers. The application was filed on December 12, 2025, under application number 19418139.
US20260097161A1, Extracorporeal Circulation System, Shenzhen Wecan
US20260097161A1, Extracorporeal Circulation System, Shenzhen Wecan
Manta MedTech Osmotic Drug Chamber System with Fixed Dose Size for Wearable Medical Devices
USPTO published patent application US20260097165A1 for Manta MedTech LLC's osmotic drug chamber system with fixed dose size designed for active wearable medical devices. The system incorporates an osmotic chamber with osmotic agent, permeability module for fluid ingress, drug chamber, compressible piston for longitudinal movement, valve module regulating drug release, fluid chamber with semipermeable membrane, and drug delivery outlets. The filing date was December 11, 2025.
DRIVE SPRING AND NEEDLE COVER SPRING FOR AN INJECTION DEVICE
USPTO published patent application US20260097167A1 filed on December 11, 2025, Application No. 19416083. The application by inventors Glauser, Tschirren, Loser, and Schrul covers an injection device with a drive spring and needle cover spring mechanism for drug delivery. The device includes a housing, a drive member for dispensing drugs, and a needle cover movable between covering and retracted positions that compress or expand the spring member.
Rapid Conjugate Vaccine Manufacturing Method, Inventprise
Rapid Conjugate Vaccine Manufacturing Method, Inventprise
Fluorescent Probe Compounds for Tumor-Targeted Imaging and Synthesis Methods
USPTO published patent application US20260097137A1 by Hebei Medical University for fluorescent probe compounds utilizing a pyrrolo[2,3-d]pyrimidine core structure conjugated to a fluorescent dye for tumor-targeted imaging. The probes demonstrate high affinity and selectivity for tumor cells, rapid clearance from normal tissues, and prolonged retention at tumor sites. The invention enables in vitro and in vivo tracking, receptor affinity studies, and intraoperative navigation applications.
GIP/GLP-1 Dual Agonist Formulations for Metabolic and Liver Disorders
The USPTO published patent application US20260097126A1 disclosing pharmaceutical formulations of small molecule GIP/GLP-1 dual receptor agonists for treating metabolic and liver disorders. The application (No. 18995773) was filed on July 18, 2023, by inventors Brian Lian, Geoffrey E. Barker, Maureen Barnes, Brahmachary Enugurthi, and Jake Gonzalez. The formulations include compounds classified under CPC codes A61K 47/548, A61K 9/0019, and others, with therapeutic applications targeting A61P 3/06 (metabolic disorders).
CD19/CD22 CAR T Cell Treatment for High-Risk Pediatric Acute Lymphoblastic Leukemia
The USPTO published patent application US20260097122A1 for CD19/CD22 chimeric antigen receptor (CAR) T-cell products and methods for treating high-risk or relapsed CD19+ or CD22+ haematological malignancies, specifically pediatric acute lymphoblastic leukemia. The application was filed on May 10, 2023, under application number 18862269. Inventors include Martin Pulé, Persis Amrolia, and Sara Ghorashian.
Oncolytic Vaccinia Viruses and Recombinant Viruses and Methods of Use Thereof
The USPTO published patent application US20260097116A1 by ViroMissile, Inc. covering clonal strains of vaccinia virus engineered as oncolytic virus therapies for treating cancer. The application includes claims for recombinant vaccinia viruses with inactivating mutations and heterologous gene products, pharmaceutical compositions, and methods of use for anti-tumor therapy.
Epigenetic Editing Tool for Targeting Hepatitis B Virus Gene
USPTO published patent application US20260097133A1 for an epigenetic editing tool targeting hepatitis B virus genes, filed by inventors Wenbo Peng, Junzheng Zhao, Shaoshuai Mao, Leilei Wu, Di Sun, Ruimin Lv, Ying Zang, and Junjian Liu on December 4, 2025. The application covers compositions and methods for epigenetic modification of HBV genes for therapeutic use in biomedicine.
Goggles with Lens Change Systems and Methods of Using the Same
USPTO published patent application US20260096929A1 for goggles with a removable lens change system. The application, filed December 12, 2025, by inventors Robin Grieves, Claes Nellestam, Magnus Gustavsson, Oscar Huss, Ilango Lourdudoss, Sofie Berglund, and Tilda HÃ¥ll, covers a goggle frame with retention features for securing a lens assembly that can be removed by actuating one of the retention features. The patent does not impose any compliance obligations on third parties.
Surgical System with Sensor Diagnostic Arrangement
USPTO published patent application US20260096925A1 for a surgical system with sensor diagnostic arrangement, filed October 3, 2024 by inventors Vadim Gliner and Assaf Govari. The system includes a handpiece, pumping module, pressure sensor assembly with at least three sensors positioned along the fluid flow path, and a controller that processes pressure data in accordance with pumping module rotation rate to determine sensor output status.
Diathermy Probes for Ophthalmic Surgery, Apr 09
Diathermy Probes for Ophthalmic Surgery, Apr 09
Eye Shield Device Patent Application US20260096930A1
The USPTO published patent application US20260096930A1 for an eye shield device invented by Laura Seymour. The application (No. 18907035) was filed on October 4, 2024, and covers a protective eye shield with multiple wearing configurations including headband and over-ear versions. The device features a cantilevered arm structure, may include cross-member arms, and uses rigid yet flexible materials such as polymer plastics, metals, or alloys.
Hygiene Product Dispenser Patent Application A1
USPTO published patent application US20260096937A1 for a hygiene product providing device filed by Kitasumi et al. The device comprises a housing configured to accommodate stacked hygiene products, a takeout port positioned below a front surface portion, and a shutter mechanism that exposes only the lowermost product when opened. The application was published April 9, 2026, with a filing date of October 8, 2025.
Methods and Compositions for Designing and Selecting TinyRNAs to Maximize Target Cleavage
USPTO published patent application US20260098266A1 by Kotaro NAKANISHI disclosing methods for designing and selecting tinyRNAs with guide RNA and Argonaute molecules for gene expression regulation in biotherapeutic and diagnostic applications. The application was filed April 1, 2024, and published April 9, 2026.
Exon 44 Duchenne Muscular Dystrophy Cyclic Peptide Antisense
The USPTO published patent application US20260098262A9 covering compositions comprising a cyclic peptide and an antisense compound targeting exon 44 of the DMD gene for Duchenne Muscular Dystrophy treatment. The application was filed on August 30, 2022, under application number 18688083, listing nine inventors including Xiang Li, Ziqing Qian, and others. No compliance obligations or deadlines are associated with this publication. This patent application publication represents a formal administrative record from the USPTO but does not create any regulatory obligations or deadlines for affected parties. Pharmaceutical and biotechnology companies developing exon-skipping therapies for DMD may wish to review the claims for potential freedom-to-operate implications.
Modified Double-Stranded RNA Agents Inhibit Gene Expression
USPTO published patent application US20260098263A1 for modified double-stranded RNA (dsRNA) agents capable of inhibiting gene expression. The application was published April 9, 2026, with inventors Martin MAIER, Don FOSTER, Stuart MILSTEIN, Satya KUCHIMANCHI, Vasant JADHAV, Kallanthottathil RAJEEV, Muthiah MANOHARAN, and Rubina PARMAR. The dsRNA agents contain thermally destabilizing nucleotides positioned opposite the seed region of the antisense strand and modified nucleotides with reduced steric bulk, with pharmaceutical compositions and therapeutic methods for treating disease conditions also disclosed.
Self-Circularized RNA Preparation Method, Apr 09
Self-Circularized RNA Preparation Method, Apr 09
Antibody-Drug Conjugate Targeting GRP94 for Cancer Treatment
The USPTO published patent application US20260097129A1 for an antibody-drug conjugate comprising a drug and an antibody specifically binding to GRP94 (glucose-regulated protein 94) or an antigen-binding fragment thereof. The invention includes a pharmaceutical composition for treating cancer, leveraging strong internalization activity against GRP94-overexpressed carcinomas. The conjugate effectively inhibits growth of cetuximab-resistant colorectal cancer cell lines including HT29, HCT116, HCT8, and LoVo cells.
Liquid Formulation of Belumosudil - Kadmon Corporation
USPTO published patent application US20260097036A1 by Kadmon Corporation on April 9, 2026, covering liquid formulations comprising belumosudil, an immunosuppressive agent used in the treatment of subjects. The application was filed on September 20, 2023, under Application No. 19113101, with inventors Olivier Schueller, Galit Regev, Mark Beville, and Nazim Kanji. The published application includes claims directed to liquid pharmaceutical compositions of belumosudil and processes for preparing such formulations.
Kyoto University Pancreatic Endoderm Cell Production Method
USPTO published patent application US20260097083A1 by Kyoto University for a method of producing pancreatic endoderm cells involving culturing the cells in a medium containing a ROCK inhibitor combined with KGF and/or EGF. The application names inventors Kenji Osafune, Yu Hatano, and Azuma Kimura, with CPC classifications spanning A61K 35/39 and C12N 5/0676.
Floating IPN Drug Delivery System for Extended Release
USPTO published patent application US20260096986A1 covering pharmaceutical compositions with a floating interpenetrating polymer network (IPN) system for drug delivery. The compositions contain at least one IPN forming system, at least one drug, and at least one gas generating agent. Upon oral ingestion, the compositions form a floating IPN in situ that provides extended release of the entrapped drug for at least approximately 3 hours. The application was filed on December 12, 2025, under application number 19418060.
BlueRock Therapeutics LP Graft-Related Arrhythmia Treatment Patent Application
The USPTO published patent application US20260097012A1 by BlueRock Therapeutics LP on April 9, 2026, disclosing methods of treating or preventing graft-related arrhythmia in cardiac graft patients by administering combinations of anti-arrhythmic agents including amiodarone, metoprolol, ivabradine, and mexiletine. The application was originally filed on September 27, 2023. This published application makes the invention publicly available for examination and potential licensing or competitive intelligence purposes.
Magics Beach Grill Reopens After Cold-Holding Temperature Violations
The Hawaii Department of Health authorized the reopening of Magics Beach Grill in Kailua-Kona on April 12, 2026, after the restaurant corrected critical food safety violations that prompted a red 'closed' placard on April 9. Violations included multiple foods held above the required 41°F cold-holding temperature and non-compliant refrigeration units. The establishment disposed of affected foods, serviced refrigeration equipment, and retrained employees before receiving authorization to resume operations.
SNIPR Biome ApS - Treating and Preventing Microbial Infections
USPTO published patent application US20260098259A1 assigned to SNIPR Biome ApS, covering methods for treating microbial infections including acute conditions such as sepsis, septicemia, SIRS, and septic shock. The application also discloses methods for controlling microbiologically influenced corrosion (MIC) and biofouling in industrial or domestic systems.
Enterin Patents Novel Aminosterol ENT-03 Compounds and Compositions
The USPTO published patent application US20260098052A1 for Enterin, Inc., covering novel aminosterol ENT-03 compounds, compositions comprising the same, and methods of making and using the same. The inventors are Denise Barbut and Michael Zasloff. The application was filed December 10, 2025, under application number 19415736. The CPC classifications indicate therapeutic applications including nervous system conditions (A61P 25/00).
Multimeric T-Cell Modulatory Polypeptides and Methods of Use Thereof
The USPTO has published patent application US20260097127A1 for multimeric T-cell modulatory polypeptides comprising immunomodulatory polypeptides and epitope-presenting Wilms tumor peptides. The application, filed October 6, 2025, names Saso Cemerski, Rodolfo J. Chaparro, Ronald D. Seidel III, and John F. Ross as inventors. The published application covers methods for modulating T-cell activity and immune responses using the disclosed polypeptides.
Protein Purification Using Chemically Activated Carbon at 0.1-15 wt%
USPTO published patent application US20260098056A1 for a method of purifying proteins from fermentation-derived solutions using chemically activated carbon. The method involves contacting the solution with 0.1-15 wt% activated carbon at pH 4-12 and temperature 2-60°C. Inventors: Sebastian Schoof, Thomas Kaeding, Gabriele Iffland. Application filed October 6, 2025.
IL-8 Signal Inhibitor Composition for Prophylaxis or Treatment of IL-8 Related Diseases
USPTO published patent application US20260098086A1 on April 9, 2026, covering compositions for prophylaxis or treatment of IL-8 related diseases using IL-8 signal inhibitors and anti-IL-8 antibodies. The application was filed December 5, 2025, by inventors Ayako KAKIUCHI, Atsuhiko Kato, Shuji Hayashi, Izumi Yanagisawa, Ryo Konno, Sachiho Netsu, and Tadashi Sankai. The published application contains CPC classifications related to antibodies and therapeutic compositions.
Dosages of Emactuzumab for TGCT Treatment, SYNOX Therapeutics
The USPTO published patent application US20260098087A1 by SYNOX Therapeutics UK Limited covering dosage regimens of emactuzumab, an anti-CSF-1R antibody, for treating tenosynovial giant cell tumour (TGCT). The application, filed October 20, 2025, describes treatment regimes and methods using the colony stimulating factor-1 receptor-binding antibody. The application is now publicly available as part of the standard patent examination process.
AMD Treatment with VEGF Antagonist Dosing at 8 or 12 Weeks
USPTO published patent application US20260098085A1 titled 'Methods for Treating Age-Related Macular Degeneration.' The application covers methods for reducing treatment burden for patients with intraocular neovascular disorders by administering VEGF antagonists on 8-week and/or 12-week dosing schedules. Inventors include Margarita Gekkieva, Peter Sallstig, Werner Schmidt, James Warburton, and Andreas Weichselberger. The application was filed on June 25, 2025.
Mammalian Cell SHMT2 Reduction for Protein Production
USPTO published patent application US20260098081A1 disclosing isolated mammalian cells with reduced or eliminated SHMT2 expression and methods for using such cells in recombinant protein production. The application names Samuel Peters, James Ravellette, David Razafsky, Jason A. Gustin, and Trissa Borgschulte as inventors. Filing date was September 29, 2023, under application number 19112697.
Get daily alerts for healthcare & life sciences
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
1,645 changes in last 7 days
Latest high priority updates
Browse Categories
375 official sources tracked
Get Healthcare & Life Sciences alerts
Daily digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get Healthcare & Life Sciences alerts
We'll email you when new healthcare & life sciences changes are detected.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.